Cognition shares surge 15.54% intraday after regaining Nasdaq compliance and confirming FDA alignment on Alzheimer's drug.

Cognition Therapeutics (CGTX) surged 15.54% intraday after reports indicated a significant intraday rebound following a sharp selloff in which the stock had previously dropped over 21% from its opening price. The dramatic intraday turnaround suggests a recovery driven by short-term investor sentiment and potential bargain hunting after the steep decline. While recent news primarily highlighted positive developments such as FDA alignment for its Alzheimer’s treatment and progress in clinical trials, these occurred prior to the current session. Therefore, the intraday bounce appears to reflect market reaction and positioning rather than new fundamental news.